Evidence map›Paper›PMID 20402772›Full record

ArticleFEMS immunology and medical microbiology2010

Induction of neutralizing antibodies in mice immunized with an amino-terminal polypeptide of Streptococcus mutans P1 protein produced by a recombinant Bacillus subtilis strain.

Milene B Tavares, Bruno M Silva, Rafael C M Cavalcante, Renata D Souza, Wilson B Luiz, Juliano D Paccez, Paula J Crowley, L Jeannine Brady, Luís C S Ferreira, Rita C C Ferreira

Open access · bronzeAbstract read
In one paragraph

Article in FEMS immunology and medical microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Vaccines · 2025
    Review
  2. Review
  3. Streptococcus mutans glutamate binding protein (GlnH) as antigen target for a mucosal anti-caries vaccine.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Milene B TavaresDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, SP, Brazil.
Bruno M Silva
Rafael C M Cavalcante
Renata D Souza
Wilson B Luiz
Juliano D Paccez
Paula J Crowley
L Jeannine Brady
Luís C S Ferreira
Rita C C Ferreira
Universidade de São Paulo · BRUniversity of Florida · US

Funding

IMMUNOMODULATION BY EXOGENOUS STREPTOCOCCAL ANTIBODYR01DE013882 · NIDCR · UNIVERSITY OF FLORIDA · PI BRADY, L. JEANNINE · 2000 to 2010
$2.9M
NIDCR NIH HHS R01 DE013882NIDCR NIH HHS R01 DE13882
6 · The paper itself

Abstract

The oral pathogen Streptococcus mutans expresses a surface protein, P1, which interacts with the salivary pellicle on the tooth surface or with fluid-phase saliva, resulting in bacterial adhesion or aggregation, respectively. P1 is a target of protective immunity. Its N-terminal region has been associated with adhesion and aggregation functions and contains epitopes recognized by efficacious antibodies. In this study, we used Bacillus subtilis, a gram-positive expression host, to produce a recombinant N-terminal polypeptide of P1 (P1(39-512)) derived from the S. mutans strain UA159. Purified P1(39-512) reacted with an anti-full-length P1 antiserum as well as one raised against intact S. mutans cells, indicating preserved antigenicity. Immunization of mice with soluble and heat-denatured P1(39-512) induced antibodies that reacted specifically with native P1 on the surface of S. mutans cells. The anti-P1(39-512) antiserum was as effective at blocking saliva-mediated aggregation of S. mutans cells and better at blocking bacterial adhesion to saliva-coated plastic surfaces compared with the anti-full-length P1 antiserum. In addition, adsorption of the anti-P1 antiserum with P1(39-512) eliminated its ability to block the adhesion of S. mutans cells to abiotic surfaces. The present results indicate that P1(39-512), expressed and purified from a recombinant B. subtilis strain, maintains important immunological features of the native protein and represents an additional tool for the development of anticaries vaccines.

Indexed as

Adhesins, BacterialAnimalsAntibodies, BacterialAntibodies, NeutralizingBacillus subtilisBacterial AdhesionGenetic VectorsMiceMice, Inbred BALB CRecombinant ProteinsStreptococcus mutansAdhesins, BacterialAntibodies, BacterialAntibodies, NeutralizingRecombinant Proteins

Identifiers

PMID20402772
PMCPMC4369793
OpenAlexW1596018450

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.